These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 19381019)

  • 1. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
    Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
    J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma.
    Hadari Y; Schlessinger J
    J Clin Invest; 2009 May; 119(5):1077-9. PubMed ID: 19422094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.
    Du X; Lin BC; Wang QR; Li H; Ingalla E; Tien J; Rooney I; Ashkenazi A; Penuel E; Qing J
    Clin Cancer Res; 2014 Dec; 20(24):6324-35. PubMed ID: 25326231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer.
    Gust KM; McConkey DJ; Awrey S; Hegarty PK; Qing J; Bondaruk J; Ashkenazi A; Czerniak B; Dinney CP; Black PC
    Mol Cancer Ther; 2013 Jul; 12(7):1245-54. PubMed ID: 23657946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
    Xin X; Abrams TJ; Hollenbach PW; Rendahl KG; Tang Y; Oei YA; Embry MG; Swinarski DE; Garrett EN; Pryer NK; Trudel S; Jallal B; Mendel DB; Heise CC
    Clin Cancer Res; 2006 Aug; 12(16):4908-15. PubMed ID: 16914579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.
    Du X; Wang QR; Chan E; Merchant M; Liu J; French D; Ashkenazi A; Qing J
    Cancer Res; 2012 Nov; 72(22):5843-55. PubMed ID: 23019225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity.
    Yin Y; Djakovic S; Marsters S; Tien J; Peng J; Tremayne J; Lee G; Neve RM; Wu Y; Merchant M; Ashkenazi A; Carter PJ
    Mol Cancer Ther; 2015 Oct; 14(10):2270-8. PubMed ID: 26269606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
    Martínez-Torrecuadrada JL; Cheung LH; López-Serra P; Barderas R; Cañamero M; Ferreiro S; Rosenblum MG; Casal JI
    Mol Cancer Ther; 2008 Apr; 7(4):862-73. PubMed ID: 18413799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants.
    Yang Y; Suhasini AN; Jiang Z; Liu N; Rosconi M; Zhang B; Li Y; Dudgeon D; Seong C; Kim S; Rafique A; Huang T; Bhosle S; Krueger P; Ullman E; Olson W; Lin JC; Shen Y; Daly C
    Cancer Res; 2024 Jul; 84(13):2169-2180. PubMed ID: 39082679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
    Meyer AN; McAndrew CW; Donoghue DJ
    Cancer Res; 2008 Sep; 68(18):7362-70. PubMed ID: 18794123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
    Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
    Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daidzein exerts anti-tumor activity against bladder cancer cells via inhibition of FGFR3 pathway.
    He Y; Wu X; Cao Y; Hou Y; Chen H; Wu L; Lu L; Zhu W; Gu Y
    Neoplasma; 2016; 63(4):523-31. PubMed ID: 27268915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
    Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
    Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
    Plowright EE; Li Z; Bergsagel PL; Chesi M; Barber DL; Branch DR; Hawley RG; Stewart AK
    Blood; 2000 Feb; 95(3):992-8. PubMed ID: 10648414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
    Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
    Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
    Martínez-Torrecuadrada J; Cifuentes G; López-Serra P; Saenz P; Martínez A; Casal JI
    Clin Cancer Res; 2005 Sep; 11(17):6280-90. PubMed ID: 16144932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.
    Salazar L; Kashiwada T; Krejci P; Meyer AN; Casale M; Hallowell M; Wilcox WR; Donoghue DJ; Thompson LM
    PLoS One; 2014; 9(1):e86470. PubMed ID: 24466111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
    Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
    Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
    J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
    Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
    Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.